Masimo Co. (NASDAQ:MASI) Stock Holdings Lowered by Ace Management Global Ltd.

Ace Management Global Ltd. lowered its position in shares of Masimo Co. (NASDAQ:MASI) by 9.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 965,504 shares of the medical equipment provider’s stock after selling 95,415 shares during the period. Masimo makes up approximately 38.4% of Ace Management Global Ltd.’s portfolio, making the stock its largest position. Ace Management Global Ltd. owned approximately 1.82% of Masimo worth $128,731,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. NBC Securities Inc. increased its holdings in shares of Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares in the last quarter. GAMMA Investing LLC increased its holdings in Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares during the last quarter. HHM Wealth Advisors LLC lifted its stake in Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the period. Finally, Lazard Asset Management LLC boosted its holdings in shares of Masimo by 5,730.0% during the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 573 shares during the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on MASI shares. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Friday, September 20th. BTIG Research lifted their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Piper Sandler reissued an “overweight” rating on shares of Masimo in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $145.33.

Masimo Stock Up 0.1 %

Shares of MASI stock opened at $144.22 on Friday. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55. Masimo Co. has a 12 month low of $75.36 and a 12 month high of $153.93. The stock has a market cap of $7.67 billion, a P/E ratio of 98.11 and a beta of 0.99. The company has a 50 day simple moving average of $129.44 and a two-hundred day simple moving average of $125.31.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.77 by $0.09. The firm had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. Masimo’s revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.62 EPS. On average, research analysts expect that Masimo Co. will post 3.88 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.